SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin gets USFDA’s nod to market generic Fenofibrate Tablets

30 Dec 2011 Evaluate

Pharma Major Lupin has received US Food and Drug Administration (USFDA) nod to market generic Fenofibrate Tablets, a cholesterol lowering drug, in the American market. The company has got the approval to sell 48 mg and 145 mg of generic Fenofibrate tablets in the American market. However, the company did not revealed the possible launch date of the product.

Earlier Abbott, the innovator of the drug, had filed patent litigations against seven firms, out of which five including those against Lupin and Teva have been settled. Abbott sells the drug under Tricor brand.

Further, Lupin could launch its generic version as early as July next year.

Earlier in December, Lupin’s US subsidiary - Lupin Pharmaceuticals, Inc. (LPI) received tentative approval for its Duloxetine Hydrochloride Delayed-release (HCL DR) Capsules 20 mg, 30 mg and 60 mg from the United States Food and Drugs Administration (USFDA) for the company’s Abbreviated New Drug Application (ANDA) to market a generic version of Eli Lily & Company’s Cymbalta Delayed-release Capsules.

Lupin has a vibrant presence in the Indian pharmaceuticals market and has over the past several years made major strides in expanding its therapy portfolio. The company has a robust promotion and distribution setup along with a strong presence in various therapeutic areas, including the fast growing diabetes market.

Lupin Share Price

2324.25 -2.25 (-0.10%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×